GlassScriptPhysician profile
Paris Bath
NPI 1770343493
$735.04
in general payments reported to CMS, 2019-2025
15 companies · $535 in 2025
The $535 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $200 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $137.80 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $130.88 | 2024-2025 | |
| Amgen INC. | $85.40 | 2024-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $53.51 | 2024-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $47.16 | 2024-2025 | Acthar |
| Novo Nordisk INC | $46.95 | 2025 | Wegovy |
| Lilly USA, LLC | $34.76 | 2025 | Zepbound, Mounjaro |
| Organon LLC | $33.20 | 2025 | Nexplanon, Hadlima, Renflexis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.51 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $28.33 | 2025 | Voquezna |
| Ucb, INC. | $24.47 | 2025 | Bimzelx |
| Otsuka America Pharmaceutical, INC. | $24.27 | 2025 | Rexulti |
| Viatris Specialty LLC | $21.61 | 2025 | Yupelri |
| Janssen Biotech, INC. | $19.38 | 2024 | Tremfya |
| Glaxosmithkline, LLC. | $16.81 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paris Bath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.